Raymond James Financial Inc. Takes Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Raymond James Financial Inc. purchased a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 545,440 shares of the company's stock, valued at approximately $42,593,000. Raymond James Financial Inc. owned about 1.10% of Prestige Consumer Healthcare as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Kestra Investment Management LLC bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $27,000. Huntington National Bank lifted its stake in shares of Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company's stock worth $46,000 after acquiring an additional 181 shares during the last quarter. Covestor Ltd increased its holdings in Prestige Consumer Healthcare by 95.6% during the 3rd quarter. Covestor Ltd now owns 1,338 shares of the company's stock worth $96,000 after purchasing an additional 654 shares during the period. GAMMA Investing LLC increased its holdings in Prestige Consumer Healthcare by 18.9% during the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock worth $108,000 after purchasing an additional 220 shares during the period. Finally, Blue Trust Inc. increased its holdings in Prestige Consumer Healthcare by 24.8% during the 4th quarter. Blue Trust Inc. now owns 2,190 shares of the company's stock worth $158,000 after purchasing an additional 435 shares during the period. 99.95% of the stock is owned by institutional investors.

Remove Ads

Prestige Consumer Healthcare Stock Up 1.1 %

Shares of NYSE:PBH traded up $0.94 during trading on Friday, reaching $83.77. The stock had a trading volume of 258,095 shares, compared to its average volume of 333,965. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $4.15 billion, a P/E ratio of 19.62, a PEG ratio of 2.69 and a beta of 0.46. The firm's 50-day simple moving average is $81.47 and its 200 day simple moving average is $78.27. Prestige Consumer Healthcare Inc. has a one year low of $62.35 and a one year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on PBH shares. StockNews.com downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Monday, March 10th. Canaccord Genuity Group raised their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Oppenheimer raised their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Finally, Sidoti downgraded Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of "Moderate Buy" and an average target price of $92.60.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.